Literature DB >> 26636545

Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension.

K M Antoniou1, G A Margaritopoulos1, N S Goh2, K Karagiannis2, S R Desai3, A G Nicholson4, N M Siafakas5, J G Coghlan6, C P Denton6, D M Hansell2, A U Wells2.   

Abstract

OBJECTIVE: To assess the prevalence of combined pulmonary fibrosis and emphysema (CPFE) in systemic sclerosis (SSc) patients with interstitial lung disease (ILD) and the effect of CPFE on the pulmonary function tests used to evaluate the severity of SSc-related ILD and the likelihood of pulmonary hypertension (PH).
METHODS: High-resolution computed tomography (HRCT) scans were obtained in 333 patients with SSc-related ILD and were evaluated for the presence of emphysema and the extent of ILD. The effects of emphysema on the associations between pulmonary function variables and the extent of SSc-related ILD as visualized on HRCT and echocardiographic evidence of PH were quantified.
RESULTS: Emphysema was present in 41 (12.3%) of the 333 patients with SSc-related ILD, in 26 (19.7%) of 132 smokers, and in 15 (7.5%) of 201 lifelong nonsmokers. When the extent of fibrosis was taken into account, emphysema was associated with significant additional differences from the expected values for diffusing capacity for carbon monoxide (DLco) (average reduction of 24.1%; P < 0.0005), and the forced vital capacity (FVC)/DLco ratio (average increase of 34.8%; P < 0.0005) but not FVC. These effects were identical in smokers and nonsmokers. Multivariate analysis showed that the presence of emphysema had a greater effect than echocardiographically determined PH on the FVC/DLco ratio, regardless of whether it was analyzed as a continuous variable or using a threshold value of 1.6 or 2.0.
CONCLUSION: Among patients with SSc-related ILD, emphysema is sporadically present in nonsmokers and is associated with a low pack-year history in smokers. The confounding effect of CPFE on measures of gas exchange has major implications for the construction of screening algorithms for PH in patients with SSc-related ILD.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Year:  2016        PMID: 26636545     DOI: 10.1002/art.39528

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  21 in total

1.  Reliance on Pulmonary Function Tests in Assessment of Systemic Sclerosis Patients for Pulmonary Hypertension: Comment on the Article by Antoniou et al.

Authors:  Lesley Ann Saketkoo; Virginia D Steen; Matthew R Lammi
Journal:  Arthritis Rheumatol       Date:  2017-01       Impact factor: 10.995

2.  Screening for Myositis Antibodies in Idiopathic Interstitial Lung Disease.

Authors:  Lee Fidler; Irena Doubelt; Sonja Kandel; Jolene H Fisher; Shikha Mittoo; Shane Shapera
Journal:  Lung       Date:  2019-03-05       Impact factor: 2.584

3.  Comparison of physiological responses after incremental shuttle walking test and 6-minute walk test in patients with systemic sclerosis.

Authors:  Buse Ozcan Kahraman; Aylin Tanriverdi; Nazenin Hande Sezgin; Serap Acar; Ahmet Merih Birlik; Aydan Koken Avsar; Bahri Akdeniz; Ebru Ozpelit; Sema Savci
Journal:  Wien Klin Wochenschr       Date:  2022-09-26       Impact factor: 2.275

4.  The disconnect between visual assessment of air trapping and lung physiology for assessment of small airway disease in scleroderma-related interstitial lung disease: An observation from the Scleroderma Lung Study II Cohort.

Authors:  Sangmee Sharon Bae; Lila Pourzand; Grace Hyun Kim; Bianca E Villegas; Andrea Oh; Daniel E Furst; Jonathan Goldin; Donald P Tashkin
Journal:  J Scleroderma Relat Disord       Date:  2021-10-23

5.  Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease.

Authors:  Joseph Jacob; Jin Woo Song; Hee-Young Yoon; Gary Cross; Joseph Barnett; Wen Ling Woo; Fern Adams; Maria Kokosi; Anand Devaraj; Elisabetta Renzoni; Toby M Maher; Dong Soon Kim; Athol U Wells
Journal:  EBioMedicine       Date:  2018-01-31       Impact factor: 8.143

Review 6.  Evaluation and management approaches for scleroderma lung disease.

Authors:  Sara R Schoenfeld; Flavia V Castelino
Journal:  Ther Adv Respir Dis       Date:  2017-06-16       Impact factor: 4.031

7.  Emphysema formation in a never-smoker with scleroderma-related interstitial pneumonia.

Authors:  Hideaki Yamakawa; Tamiko Takemura; Tomohisa Baba; Takashi Ogura
Journal:  Respir Med Case Rep       Date:  2018-09-13

8.  Balanced Wnt/Dickkopf-1 signaling by mesenchymal vascular progenitor cells in the microvascular niche maintains distal lung structure and function.

Authors:  Megan E Summers; Bradley W Richmond; Jonathan A Kropski; Sarah A Majka; Julie A Bastarache; Antonis K Hatzopoulos; Jeffery Bylund; Moumita Ghosh; Irina Petrache; Robert F Foronjy; Patrick Geraghty; Susan M Majka
Journal:  Am J Physiol Cell Physiol       Date:  2020-10-21       Impact factor: 4.249

9.  Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?

Authors:  Hideaki Yamakawa; Tamiko Takemura; Tae Iwasawa; Yumie Yamanaka; Satoshi Ikeda; Akimasa Sekine; Hideya Kitamura; Tomohisa Baba; Shinichiro Iso; Koji Okudela; Kazuyoshi Kuwano; Takashi Ogura
Journal:  BMC Pulm Med       Date:  2018-01-30       Impact factor: 3.317

10.  Functional associations of pleuroparenchymal fibroelastosis and emphysema with hypersensitivity pneumonitis.

Authors:  Joseph Jacob; Arlette Odink; Anne Laure Brun; Claudio Macaluso; Angelo de Lauretis; Maria Kokosi; Anand Devaraj; Sujal Desai; Elisabetta Renzoni; Athol U Wells
Journal:  Respir Med       Date:  2018-03-30       Impact factor: 3.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.